Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma
Journal of Immunotherapy and Precision Oncology · 01.02.2024 · 7 (1) · 1-6
DOI: 10.36401/jipo-23-20 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 05.02.2024. Verfasst von Ugur Sener und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, MN, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Introduction
Proton craniospinal irradiation (pCSI) is a treatment option for leptomeningeal disease (LMD), which permits whole neuroaxis treatment while minimizing toxicity. Despite this, patients inevitably experience progression. Adding systemic therapy to pCSI may improve outcomes.
Methods
In this single-institution retrospective case series, we present the feasibility of treatment with pCSI (30Gy, 10 fractions) and an immune checkpoint inhibitor (ICI) in two sequential patients with LMD from melanoma.
Results
The first patient developed LMD related to BRAF V600E-mutant melanoma after prior ICI and BRAF-targeted therapy. After pCSI with concurrent nivolumab, the addition of relatlimab, and BRAF-targeted therapy, he remained alive 7 months after LMD diagnosis despite central nervous system progression. The second patient developed LMD related to BRAF-wildtype melanoma after up-front ICI. He received pCSI with concurrent ipilimumab and nivolumab, then nivolumab maintenance. Though therapy was held for ICI hepatitis, the patient remained progression-free 5 months after LMD diagnosis.
Conclusion
Adding an ICI to pCSI is feasible for patients with LMD and demonstrates a tolerable toxicity profile. While prospective evaluation is ultimately warranted, pCSI with ICI may confer survival benefits, even after prior ICI.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Rochester, MN, USA.
- Department of Oncology, Mayo Clinic, Rochester, MN, USA.
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Ugur Sener, Mason Webb
Förderung
- NCATS NIH HHS
Zitieren
APA
Sener, U., Webb, M., Breen, W. G., Neth, B. J., Laack, N. N., Routman, D., Brown, P. D., Mahajan, A., Frechette, K., Dudek, A. Z., Markovic, S. N., Block, M. S., McWilliams, R. R., Dimou, A., Kottschade, L. A., Montane, H. N., Kizilbash, S. H., & Campian, J. L. (2024). Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma. Journal of Immunotherapy and Precision Oncology, 7(1), 1-6. https://doi.org/10.36401/jipo-23-20
Vancouver
Sener U, Webb M, Breen WG, Neth BJ, Laack NN, Routman D, et al. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma. Journal of Immunotherapy and Precision Oncology. 2024;7(1):1-6. doi:10.36401/jipo-23-20
BibTeX
@article{Sener2024,
author = {Sener, Ugur and Webb, Mason and Breen, William G and Neth, Bryan J and Laack, Nadia N and Routman, David and Brown, Paul D and Mahajan, Anita and Frechette, Kelsey and Dudek, Arkadiusz Z and Markovic, Svetomir N and Block, Matthew S and McWilliams, Robert R and Dimou, Anastasios and Kottschade, Lisa A and Montane, Heather N and Kizilbash, Sani H and Campian, Jian L},
title = {Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma},
journal = {Journal of Immunotherapy and Precision Oncology},
year = {2024},
volume = {7},
number = {1},
pages = {1--6},
doi = {10.36401/jipo-23-20}
}
EUVIMED